Abiomed continues rebound, expects to file Impella PMA this fiscal year

Abiomed continues rebound, expects to file Impella PMA by end of fiscal year

Abiomed (NSDQ:ABMD) shares continued their rebound today from a plunge begun late last year after news broke of a federal investigation and new FDA requirements for its flagship Impella heart pump.

The Danvers, Mass.-based medical device company’s stock soared last week after it released its fiscal 4th-quarter and 2013 results, reporting soaring profits on solid, double-digit sales growth. Shares continued the trend today, rising about 1.5% in mid-morning trading.

In December, an FDA advisory panel recommended that some categories of heart pumps, including the Impella, be required to submit pre-market approval applications to the agency even if they’ve already been approved via the FDA’s 510(k) clearance protocol, continuing the slide for ABMD shares begun when it revealed a federal probe into its marketing of the Impella device.

Last week, chairman, president & CEO Michael Minogue told analysts during a conference call that the company expects to complete its PMA submission to the FDA by the end of fiscal 2014. The federal watchdog agency is allowing Abiomed to submit the PMA in 3 separate modules, Minogue said, consisting of preclinical testing data; manufacturing and quality systems data; and clinical data and conclusions. It’s still unclear whether the agency will ask its Circulatory Devices advisory panel to review Abiomed’s PMA before a final decision is reached, he said.

"The PMA that Abiomed intends to submit to the agency will contain all reasonably known information which includes extensive real world experience and readily available medical device reporting or MDR safety records," Minogue said during the call. "The review clock starts when the final module is submitted and the expectation is for 180 days without a panel requirement and 320 days with it. Until this is completed, everything is business as usual for Abiomed and our Impella 510(k) clearances."

Minogue said early indications are that the PMA could be granted without Abiomed having to run another clinical trial, citing its trove of data covering real-world use of the Impella pump.

"The feedback at the December panel meeting from the physicians and also the FDA indicated there could be the potential of sufficient existing data to file for PMA without doing another trial, but again we may be asked to do additional work, which could be potentially the single-arm study, prospective study or just more additional registry work or post-market analysis," he said. "We are in discussions with the agency requiring these requirements."

"We’d like to be one of the first success stories in the industry that’s converted from a 510(k) through the 515 process to PMA," Minogue added. "We’re excited to kind of be the role model.

As for the federal subpoena that kicked off Abiomed’s woes last year, Minogue said the company is still working with the U.S. Attorney’s Office for the District of Columbia "to resolve the issue and cooperate."

"We are just going to follow their path and have confidence in our ability to work with them and to resolve it one way or the other," he said. "We do not have any other comments on that."

ABMD shares were trading at $20 even as of about 11:30 this morning, up 1.5% on the day.

RSS From Medical Design & Outsourcing

  • Athermal laser machining cuts bioabsorbable polymers and more
    A the recent MD&M East trade show in New York, Norman Noble, discussed the capability of athermal laser manufacturer. The company has developed the Noble S.T.E.A.L.T.H. (System To Enable Ablation Laser Technology Haz-free). The athermal laser machining process was developed to create precise features in any material, including bioabsorbable polymers, shape memory metals and other […]
  • Exciting possibilities for metallic glass in the medical device world
    Researchers are exploring the potential of metallic glass as a versatile, pliable material that is stronger than steel, with a bevy of possible medical device applications. Yale University engineers have discovered a unique method for designing metallic glass nanostructures across a wide range of chemicals, a technique that could have applications for everything from watch […]
  • Strong Precision Technologies’ medical divisions to unify under MedTorque brand
    Strong Precision Technologies announced on July 2, 2015, that its two medical divisions will now go to market under a single brand, MedTorque. The move reflects the increasing integration of the division formerly known as Inland Midwest with MedTorque, its sister division in Kenosha, WI. “We will continue providing our customers with the personalized level of service […]
  • Olympus offers next-day product replacement guarantee for medical devices
    Olympus, a medical and surgical procedures solutions company, announced that it is guaranteeing next-day replacements for surgical equipment at no additional charge. Olympus is the first surgical product manufacturer to offer this type of guarantee. The service became available to customers with an Olympus Full Service Agreement earlier this year. “Canceled procedures can be costly for healthcare facilities […]
  • More accurate prediction on prognosis in multiple myeloma from SkylineDx
    SkylineDx, a biotechnology company specializing in the development and commercialization of genetic tests, is launching its MMprofiler assay. This test enables clinicians to more accurately predict the prognosis of patients with multiple myeloma (bone marrow cancer) than traditional methods. The MMprofiler measures the activity of 92 genes which are directly or indirectly related to the […]
  • Flint Mobile swaps card reader for camera, accept mobile payments anywhere
    Flint Mobile, the swipe-free mobile payments app, has significantly expanded its payment management and loyalty capabilities for small, service-centric businesses, like the ones run by on-the-go medical equipment professionals. The toggle-free mobile technology makes the process quite simple for both parties, as all transactions are conducted through the mobile device’s camera without the need of any external […]
  • Should scientists be allowed to genetically alter human embryos?
    Scientists have at their disposal, a way to explore the possible prevention of genetic diseases before birth. But should they? Currently, the most promising path forward involves editing the genes of human embryos, a procedure threaded with controversy. An article in “Chemical & Engineering News” (C&EN), the weekly newsmagazine of the American Chemical Society (ACS), parses […]
  • Tackling chronic sinusitis by addressing underlying factors
    The stuffy noses and sinus pressure of head colds are uncomfortable, but for most people, they go away within days. For those with chronic sinusitis, however, those symptoms and others drag on for weeks. Now scientists are onto a potential new therapy that could address one of the underlying factors associated with the condition. They […]
  • Implantable “artificial pancreas” could help diabetes patients control their blood sugar
    Living with Type 1 diabetes requires constant monitoring of blood sugar levels and injecting insulin daily. Now scientists are reporting in the American Chemical Society (ACS) journal, “Industrial & Engineering Chemistry Research,” the development of an implantable “artificial pancreas” that continuously measures a person’s blood sugar or glucose level and can automatically release insulin as […]
  • Drug Deactivation program roll out to all facilities for safe disposal of unused prescription medications
    Verde Technologies announced that New Brighton-based Meridian Behavioral Health, the largest for-profit substance abuse and addiction treatment group in Minnesota, has become its most recent partner in the deactivation and safe disposal of prescription medications including methadone. Meridian is the first behavioral health group to roll out the Deterra Drug Deactivation System to all 17 […]
  • Lophius Biosciences introduces T-activated ImmunoScan Cocktail
    Lophius Biosciences announced the commercial launch of T-Track ImmunoScan and T-activated ImmunoScan Cocktail. Based on a proprietary and very specific cocktail of stimulants in combination with the Company’s T-activation technology, T-Track ImmunoScan and T-activated ImmunoScan Cocktail specifically target different cell types involved in both the adaptive and innate immune system. T-Track ImmunoScan and the T-activated […]

Leave a Reply